Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization
Conditions
Interventions
Evolocumab
Placebo
Locations
226
United States
Research Site
Huntsville, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Little Rock, Arkansas, United States
Research Site
La Jolla, California, United States
Research Site
La Jolla, California, United States
Research Site
Long Beach, California, United States
Start Date
April 18, 2013
Primary Completion Date
July 12, 2016
Completion Date
July 29, 2016
Last Updated
February 20, 2019
NCT07473960
NCT06568601
NCT00353782
NCT07489209
NCT07037771
NCT07058077
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions